GlassScriptPhysician profile
Quoc Hung Tran
NPI 1871645556
$4,120.56
in general payments reported to CMS, 2019-2025
26 companies · $743 in 2025
The $743 reported for 2025 was more than what 77% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,093 · 2020: $90.15 · 2022: $373 · 2023: $1,101 · 2024: $720 · 2025: $743.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,564.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,564.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $812.04 | 2022-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $779.05 | 2019-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $467.35 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $456.59 | 2023-2025 | Caplyta |
| Corium, LLC | $277.84 | 2023-2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $162.60 | 2025 | Fanapt |
| Allergan, INC. | $141.74 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $140.92 | 2019-2023 | Jornay Pm |
| Neurocrine Biosciences, INC. | $132.49 | 2019 | |
| Lundbeck LLC | $125.73 | 2019-2024 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $77.04 | 2024-2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $75.77 | 2023-2024 | Quviviq |
| Brainsway USA INC | $57.66 | 2023 | |
| Supernus Pharmaceuticals, INC. | $51.02 | 2023 | Qelbree |
| Noven Therapeutics, LLC | $50.64 | 2023-2024 | Xelstrym, Secuado |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $50.51 | 2019 | |
| Neos Therapeutics, LP | $45.69 | 2019 | |
| Shire North American Group INC | $40.36 | 2019 | |
| Janssen Pharmaceuticals, INC | $38.98 | 2019-2020 | |
| Tris Pharma INC | $36.85 | 2022-2023 | Dyanavel Xr |
| Jazz Pharmaceuticals INC. | $23.35 | 2019 | |
| Validus Pharmaceuticals LLC | $20.22 | 2024 | Equetro |
| Almatica Pharma LLC | $20.03 | 2024 | Loreev Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $12.45 | 2022 | |
| Alfasigma USA, INC. | $12.27 | 2022 | |
| Aytu Biopharma, INC. | $11.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Quoc Hung Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.